Up And Up Pain

Camphor, Menthol, And Methyl Salicylate


Target Corporation
Human Otc Drug
NDC 82442-213
Up And Up Pain also known as Camphor, Menthol, And Methyl Salicylate is a human otc drug labeled by 'Target Corporation'. National Drug Code (NDC) number for Up And Up Pain is 82442-213. This drug is available in dosage form of Patch. The names of the active, medicinal ingredients in Up And Up Pain drug includes Camphor (synthetic) - 12 mg/1 Menthol - 57 mg/1 Methyl Salicylate - 63 mg/1 . The currest status of Up And Up Pain drug is Active.

Drug Information:

Drug NDC: 82442-213
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Up And Up Pain
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Camphor, Menthol, And Methyl Salicylate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Target Corporation
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Patch
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAMPHOR (SYNTHETIC) - 12 mg/1
MENTHOL - 57 mg/1
METHYL SALICYLATE - 63 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 11 Jan, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 07 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Target Corporation
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:853260
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0780707902134
UPC stands for Universal Product Code.
UNII:5TJD82A1ET
L7T10EIP3A
LAV5U5022Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
82442-213-605 PATCH in 1 CARTON (82442-213-60) / 1 PATCH in 1 PATCH11 Jan, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Uses temporarily relieves the minor aches and pains of muscles and joints associated with: sprains simple backache arthirtis strains bruises

Product Elements:

Up and up pain camphor, menthol, and methyl salicylate glyceryl rosinate lanolin petrolatum polyisobutylene (1000 mw) natural latex rubber zinc oxide camphor (synthetic) camphor (synthetic) menthol menthol methyl salicylate salicylic acid

Indications and Usage:

Directions adults and children 12 years of age and older: clean and dry affected area remove patch from film apply to affected area no more than 3 to 4 times daily do not wear patch for more than 4 hours children under 12 years of age: consult a doctor

Warnings:

Warnings for external use only allergy alert: if prone to allergic reaction from aspirin or salicylates, consult a doctor before use

Do Not Use:

Warnings for external use only allergy alert: if prone to allergic reaction from aspirin or salicylates, consult a doctor before use

When Using:

When using this product do not use otherwise than as directed avoid contact with eyes, mucous membranes or rashes do not bandage tightly discontinue use at least 1 hour before a bath or shower do not use immediately after a bath or shower

Dosage and Administration:

Distributed by: target corproation minneapolis, mn 55403 made in china

Stop Use:

Stop use and ask a doctor if redness is present or irritation or rash develops condition worsens or symptoms persist for more than 7 days symptoms clear up and occur again within a few days

Package Label Principal Display Panel:

90213


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.